Adaptive Randomization of Neratinib in Early Breast Cancer

BACKGROUND: I-SPY2, a standing, multicenter, adaptive phase 2 neoadjuvant trial ongoing in high-risk clinical stage II/III breast cancer, is designed to evaluate multiple, novel experimental agents added to standard chemotherapy for their ability to improve the rate of pathologic complete response (...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:N Engl J Med
Autores principales: Park, John W., Liu, Minetta C., Yee, Douglas, Yau, Christina, van 't Veer, Laura J., Symmans, W. Fraser, Paoloni, Melissa, Perlmutter, Jane, Hylton, Nola M., Hogarth, Michael, DeMichele, Angela, Buxton, Meredith B., Chien, A. Jo, Wallace, Anne M., Boughey, Judy C., Haddad, Tufia C., Chui, Stephen Y., Kemmer, Kathleen A., Kaplan, Henry G., Isaacs, Claudine, Nanda, Rita, Tripathy, Debasish, Albain, Kathy S., Edmiston, Kirsten K., Elias, Anthony D., Northfelt, Donald W., Pusztai, Lajos, Moulder, Stacy L., Lang, Julie E., Viscusi, Rebecca K., Euhus, David M., Haley, Barbara B., Khan, Qamar J., Wood, William C., Melisko, Michelle, Schwab, Richard, Lyandres, Julia, Davis, Sarah E., Hirst, Gillian L., Sanil, Ashish, Esserman, Laura J., Berry, Donald A.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2016
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5259558/
https://ncbi.nlm.nih.gov/pubmed/27406346
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1513750
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares